SOURCE: Spotlight Innovation Inc.

Spotlight Innovation Inc.

November 25, 2015 08:30 ET

Spotlight Innovation to Present at LD MICRO Main Event Investor Conference on Wednesday, December 2, 2015

WEST DES MOINES, IA--(Marketwired - Nov 25, 2015) - Spotlight Innovation Inc. (OTCQB: STLT) announces that President and CEO Christopher Grunewald will present at the LD MICRO Main Event Investor Conference on Wednesday, December 2, 2015 at 5:00pm Pacific Standard Time. The conference will take place from December 1-3, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Mr. Grunewald will discuss the biotechnologies being developed by Spotlight Innovation's subsidiary companies, Memcine Pharmaceuticals Inc. and Celtic Biotech Iowa Inc. Memcine Pharmaceuticals is developing its Immunoplex™ technology, a proprietary universal antibody and epitope tag used to facilitate the formation of immune complexes from vaccine antigens. Immunoplex uses the body's own naturally occurring targeting system to deliver vaccine components directly to immune cells and improve efficacy. Celtic Biotech is developing novel therapeutic products from naturally specialized receptor-binding proteins derived from snake venom. Celtic Biotech's therapeutic products have anticancer and analgesic properties applicable to the treatment of solid cancers and for pain management in humans.

Mr. Grunewald is available for one-to-one meetings on Tuesday, December 1 and Wednesday, December 2. Please contact Rudy Barrio of DresnerAllenCaron at 212-691-8087 if you would like to arrange a meeting. For more information about the LD MICRO Main Event Investor Conference, visit http://www.ldmicro.com/p/main-event.html.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies, acquires and incubates companies that have unique intellectual property (IP) in the medical sector. The Company has relationships with the nation's leading academic and institutional IP developers, and locates promising IP technologies with potential for market share capture. With strong support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at www.spotlightinnovation.com.

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Photographs of Crotalus durissus are available for the media upon request from DresnerAllenCaron by contacting Rudy Barrio at 212-691-8087.

Contact Information